Kaposi's sarcoma in AIDS. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Kaposi's sarcoma in AIDS.

Immunol Ser. 1989;44:345-58. Unique Identifier : AIDSLINE MED/91208236
Volberding PA; School of Medicine, University of California, San Francisco.

Abstract: Because Kaposi's sarcoma is a highly visible disease and one readily confirmed histologically, it continues to play an important role in the clinical spectrum of AIDS. At this time, it can not be confirmed whether AIDS-related Kaposi's sarcoma is caused by an initial viral infection, whether the development of an immune deficiency predisposes patients to develop this malignancy, or whether viral or other cofactors may be involved. Evaluation of therapies for AIDS-related Kaposi's sarcoma is made more difficult by the lack of natural history information. In addition, available drugs are often immunosuppressing and investigators have considerable concern in utilizing these therapies to treat Kaposi's sarcoma, a cancer that is intimately associated with immune deficiency. Extensive research continues on single-agent trials of cytotoxic agents as well as immune modulators and antiviral agents. Although considerable progress has been made in the treatment of AIDS-related Kaposi's sarcoma, therapeutic decision-making is extremely difficult. It is expected that additional trials and experimental agents will improve our ability to provide effective treatment.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Human Sarcoma, Kaposi's/DRUG THERAPY/*ETIOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationshumansarcoma,kaposi's/drugtherapy/KWDetiologyjournalarticlereviewreview,tutorial
910830
M9180996

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .